ReCode Therapeutics Administers Initial Dose in Phase 1b Study of RCT2100 for Cystic Fibrosis Treatment.

AstraZeneca’s Tagrisso (osimertinib) has received approval in the United States for treating adult patients with unresectable Stage III EGFRm NSCLC.

The FDA has granted IND approval for the world's first liquid recombinant Botulinum Toxin Type A formulation.

Innovent Reports NMPA NDA Approval for Picankibart (Anti-IL-23p19 Antibody) in Moderate to Severe Plaque Psoriasis Treatment.

Pfizer Voluntarily Removes All Batches of Sickle Cell Disease Drug OXBRYTA® (voxelotor) From Global Market.

Successful Phase III Trials for Genentech's Gazyva Indicate It Outperforms Standard Treatments in Lupus Nephritis Patients.

Sep. 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Sep 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Kyowa Kirin Shares Initial Results from Rocatinlimab Phase 3 ROCKET HORIZON Study in Adults with Moderate to Severe Eczema.

This report outlines the process of monoclonal antibody drug patent research with the investigation of BeiGene patent portfolio related to its tislelizumab monoclonal antibody.

UCB Unveils 4-Year BIMZELX® (bimekizumab-bkzx) Data for Moderate-to-Severe Plaque Psoriasis at EADV 2024.

Tislelizumab, referred to as bazeleus, represents a humanized IgG4 monoclonal antibody targeting PD-1.